These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7404395)

  • 1. [Study of fibrinogen degradation products in rheumatic diseases].
    Murav'ev IuV
    Ter Arkh; 1980; 52(6):84-7. PubMed ID: 7404395
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fibrin fibrinogen degradation products in the blood in systemic lupus erythematosus and other major collagen diseases].
    Wysocka K; Kiczak J
    Reumatologia; 1982; 20(1-2):15-21. PubMed ID: 7163659
    [No Abstract]   [Full Text] [Related]  

  • 3. [Studies on plasma F. XIII subunit a level and the detection of soluble fibrin monomer in collagen diseases].
    Okubo S; Suzuki H; Ishida T; Yasunaga K
    Rinsho Ketsueki; 1986 Aug; 27(8):1339-44. PubMed ID: 3795511
    [No Abstract]   [Full Text] [Related]  

  • 4. [Level of fibrinogen/fibrin degradation products (F/FDP) in certain internal diseases].
    Alakhverdian R; Denchev K
    Vutr Boles; 1979; 18(4):28-32. PubMed ID: 494629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fibrin-fibrinogen degradation products in connective tissue diseases].
    Shchepotin BM; Ena IaM; Bodaretskiĭ GM
    Revmatologiia (Mosk); 1989; (2):64-8. PubMed ID: 2678401
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical value of determining fibrin and fibrinogen degradation products in kidney diseases].
    Belitskaia GA; Ena IaM; Varetskaia TV; Shevchenko LI
    Klin Med (Mosk); 1976 Mar; 54(3):96-102. PubMed ID: 966670
    [No Abstract]   [Full Text] [Related]  

  • 7. [A comparative evaluation of methods for determining the activity of rheumatic diseases].
    Belitskaia GA; Nikula TD; Palienko IA; Shevchenko LI; Fedorova NE
    Vrach Delo; 1989 Aug; (8):25-7. PubMed ID: 2588517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Method of radial immunodiffusion by Mancini for determination of fibrin fibrinogen degradation products].
    Mikhaĭlova ND; Guseĭnov ChS; Likhacheva ZI; Gorelova AM
    Lab Delo; 1978; (8):490-3. PubMed ID: 80505
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical importance of determining fibrinogen and fibrin breakdown products in arterial hypertension].
    Ena IaM; Chernysheva LG; Taran AI; Shevchenko LI
    Sov Med; 1981; (3):6-9. PubMed ID: 7244836
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrin-fibrinogen degradation products in hepatic cirrhosis.
    Bulajić M; Kovacević N; Lalić M; Rolović Z
    Acta Med Iugosl; 1977; 31(4):333-8. PubMed ID: 596236
    [No Abstract]   [Full Text] [Related]  

  • 11. [Determination of plasma fibrinogen and fibrin degradation products (FDP) in 100 normal persons and 32 cases of acute cerebrovascular disease (author's transl)].
    Wang GX
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1982 Feb; 15(1):8-10. PubMed ID: 7094732
    [No Abstract]   [Full Text] [Related]  

  • 12. [Serum fibrinogen degradation products in various surgical conditions].
    Piecuch T; Muzała-Bogdan B
    Wiad Lek; 1982 Jun; 35(7-8):473-8. PubMed ID: 7123938
    [No Abstract]   [Full Text] [Related]  

  • 13. [The usefullness of the fibrinogen degradation products (FDP) determination in the serum and urine in diagnostics and evaluation of effectiveness of therapy of nephropathy (author's transl)].
    Kwiecien-Głowacka E
    Przegl Lek; 1981; 38(3):335-40. PubMed ID: 7244292
    [No Abstract]   [Full Text] [Related]  

  • 14. Assay of fibrin degradation products in human aqueous humour.
    Sen DK; Sarin GS
    Indian J Ophthalmol; 1981 Jul; 29(2):87-9. PubMed ID: 7199029
    [No Abstract]   [Full Text] [Related]  

  • 15. [Relations between products of fibrin degradation and arterial blood pressure in pregnancy complicated by nephropathy].
    Tsitsiashvili ESh
    Lab Delo; 1982; (4):230-2. PubMed ID: 6177910
    [No Abstract]   [Full Text] [Related]  

  • 16. [Determination of the fibrinogen/fibrin antigen content in the blood plasma and serum by radial immunodiffusion].
    Iakunin GA; Smolianitskiĭ AIa; Kurguzova OP; Grabskiĭ MA
    Lab Delo; 1982; (7):408-10. PubMed ID: 6181303
    [No Abstract]   [Full Text] [Related]  

  • 17. Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke.
    de Lau LM; Cheung EY; Kluft C; Leebeek FW; Meijer P; Laterveer R; Dippel DW; de Maat MP
    Br J Haematol; 2008 Dec; 143(5):734-7. PubMed ID: 19036017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrinogen degradation products in human CSF: a preliminary clinical study].
    Li YP
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1986 Jun; 19(3):142-5. PubMed ID: 3757627
    [No Abstract]   [Full Text] [Related]  

  • 19. [Significance of fibrin fibrinogen degradation products in the cerebrospinal fluid in the neonatal period].
    Dalens B; Bezou MJ; Coulet M; Raynaud EJ
    Ann Pediatr (Paris); 1983 Jan; 30(1):59-62. PubMed ID: 6830109
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-thymocyte globulin therapy induced a spurious increase of fibrinogen degradation products in hypoplastic myelodysplastic syndrome.
    Yahata Y; Isobe Y; Sasaki M; Oshimi K; Sugimoto K
    Eur J Haematol; 2009 May; 82(5):404. PubMed ID: 19191866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.